UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Diffuse astrocytoma (grade II)
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant astrocytomas.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Medulloblastoma
Oligodendroglioma
Pilocytic astrocytoma (grade I)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Brainstem Glioma
Diffuse Midline Glioma
Pineal Region Tumors
This phase II clinical trial tests the use of a precision medicine approach in treating pediatric patients with recurrent solid tumors, including central nervous system tumors.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Conditions
Glioma
Glioblastoma (grade IV)
This is a phase 1/2a study to assess the safety, dose-limiting toxicities, recommended Phase 2 schedule, and preliminary efficacy of aminolevulinic acid sonodynamic therapy in patients with recurrent or progressive GBM.
Conditions
Glioma
This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy, immunotherapy, and other clinically relevant drugs in gliomas.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.
Conditions
Glioma
Glioblastoma (grade IV)
This single-center Phase I/Ib study in recurrent glioblastoma (GBM) aims to establish a recommended phase 2 dose of the mTOR inhibitor RMC-552 in GBM participants as well as to evaluate safety and antitumor effect of this drug.
Conditions
Glioma
Glioblastoma (grade IV)
This phase II/III clinical trial is a response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM.